| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Calciol targets the vitamin D receptor (VDR). However, as the inactive form of vitamin D3, calciol has minimal or no activity at the VDR. It is an enantiomer of vitamin D3 and is formed as a photoproduct during the synthesis or degradation of vitamin D. Calciol's role in calcium homeostasis is indirect, as it is not the active form of vitamin D.
|
|---|---|
| ln Vitro |
The effect of normal human keratinocytes on the incorporation of 3H-thymidine into DNA was assessed in the cultured human keratinocytes. 5,6-trans-vitamin D3 only produces a noticeable reduction at 10(-6) M. Vitamin D receptor (VDR) dissociation constant for 5,6-trans-vitamin D3 is 560 nM[1].
In vitro, calciol has been studied for its effects on calcium homeostasis and vitamin D metabolism. As the inactive form of vitamin D3, calciol does not activate the vitamin D receptor or induce the expression of vitamin D-responsive genes. The compound is used as a reference standard in analytical studies of vitamin D and its metabolites. |
| ln Vivo |
In vivo, calciol is not biologically active in vitamin D-deficient chicks. The compound is an inactive form of vitamin D3 and does not contribute to calcium homeostasis through VDR-mediated effects. Calciol is primarily of interest as a photoproduct and as a reference compound in vitamin D research.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for calciol measure its affinity for the vitamin D receptor (VDR). Radioligand binding assays are performed using purified VDR or VDR-containing extracts, with radiolabeled vitamin D3 or calcitriol as ligands. The compound's ability to displace the radioligand is measured. However, calciol has minimal or no VDR binding activity, consistent with its status as the inactive form of vitamin D3.
|
| Cell Assay |
In vitro cellular studies with calciol are limited, as it is an inactive form of vitamin D3. However, the compound may be used as a negative control in studies of vitamin D signaling. Cells are treated with calciol at various concentrations, and VDR activation and downstream gene expression are measured. Calciol does not activate VDR or induce vitamin D-responsive gene expression.
|
| Animal Protocol |
In vivo animal experiments with calciol are performed in vitamin D-deficient animal models. Animals are administered calciol at various doses, and calcium homeostasis, bone metabolism, and other vitamin D-related parameters are measured. Calciol does not have biological activity in vitamin D-deficient chicks, confirming its status as an inactive form of vitamin D3.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of calciol include its lipophilicity and ability to distribute in fat tissues. The compound has the molecular formula C27H44O. Calciol is a photoproduct of vitamin D3 and appears as a white to light yellow solid powder. Storage under recommended conditions is important for stability. The compound should be protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Toxicological data for calciol are derived from vitamin D research. As the inactive form of vitamin D3, calciol is not expected to have significant toxicity. The compound is for research use only and not intended for human therapeutic applications. Standard safety precautions should be followed when handling the compound. No significant toxicity has been reported at effective doses in animal studies.
|
| References | |
| Additional Infomation |
5,6-trans-vitamin D3 is a member of the vitamin D3 family, belonging to the calcium alcohol class, with its 5-position double bond in a trans configuration. Under sunlight exposure, the vitamin D3 precursor and vitamin D3 in the skin undergo photoisomerization, converting to 5,6-trans-vitamin D3. It is a human metabolite. It belongs to the vitamin D3 family and is an open-ring cholesterol sterol, secondary alcohol, and hydroxyopen-ring sterol. Its function is related to calcium alcohol compounds. Studies have reported the detection of 5,6-trans-vitamin D3 in Solanum glaucophyllum and humans (Homo sapiens).
Calciol is also known as 5,6-trans-Vitamin D3, (3β,5E,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol, and cholecalciferol (as a related compound). It is an inactive form of vitamin D3 and an enantiomer of vitamin D3. Calciol is a photoproduct of vitamin D3 and is used as a reference standard in vitamin D research. It has important biological roles in calcium homeostasis, but only through its conversion to active vitamin D metabolites. The compound is not biologically active in vitamin D-deficient chicks. |
| Molecular Formula |
C27H44O
|
|---|---|
| Molecular Weight |
384.63766
|
| Exact Mass |
384.339
|
| Elemental Analysis |
C, 84.31; H, 11.53; O, 4.16
|
| CAS # |
22350-41-0
|
| Related CAS # |
22350-41-0
|
| PubChem CID |
5283711
|
| Appearance |
White to light yellow solid powder
|
| LogP |
7.619
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
610
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(CCC[C@H]([C@H]1CC[C@H]2/C(/CCC[C@]12C)=C/C=C1/C[C@@H](O)CCC/1=C)C)C
|
| InChi Key |
QYSXJUFSXHHAJI-FVUVGDFOSA-N
|
| InChi Code |
InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13+/t21-,24+,25-,26+,27-/m1/s1
|
| Chemical Name |
(1S,3E)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
|
| Synonyms |
5,6-trans-Cholecalciferol; 5,6-trans-Vitamin D3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethyl Acetate: ≥ 50 mg/mL (~130mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5998 mL | 12.9992 mL | 25.9983 mL | |
| 5 mM | 0.5200 mL | 2.5998 mL | 5.1997 mL | |
| 10 mM | 0.2600 mL | 1.2999 mL | 2.5998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
